# Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

> **NCT00560794** · PHASE2 · COMPLETED · sponsor: **Amgen Research (Munich) GmbH** · enrollment: 21 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Blinatumomab (MT103)

## Key facts

- **NCT ID:** NCT00560794
- **Lead sponsor:** Amgen Research (Munich) GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-09
- **Final completion:** 2014-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560794, "Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00560794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*